Matoke Holdings
Matoke Holdings is a medical device company dedicated to developing innovative solutions for chronic wounds, with a focus on outpacing antimicrobial resistance through advanced technologies such as Reactive Oxygen (RO) technology. The company aims to provide scalable, cost-effective wound care products that address the growing challenge of antimicrobial resistance and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Topical antimicrobial wound gel using reactive-oxygen delivery in a bioengineered matrix
A topical wound gel formulation that delivers reactive oxygen species (generating hydrogen peroxide in situ) using a bioengineered matrix to provide fast-acting, sustained antimicrobial action and support wound healing.
Polymeric matrix delivery platform for wound-care antimicrobials
A polymer-based delivery platform designed to release antimicrobial reactive oxygen species to modulate wound pH and microbial burden.
Topical antimicrobial wound gel using reactive-oxygen delivery in a bioengineered matrix
A topical wound gel formulation that delivers reactive oxygen species (generating hydrogen peroxide in situ) using a bioengineered matrix to provide fast-acting, sustained antimicrobial action and support wound healing.
Polymeric matrix delivery platform for wound-care antimicrobials
A polymer-based delivery platform designed to release antimicrobial reactive oxygen species to modulate wound pH and microbial burden.
Services
Preparation and support for regulatory filings and interactions with regulators, drawing on experience with multiple FDA 510(k) submissions and device classification issues.
Design and conduct of preclinical in vitro studies, case studies and clinical evaluations to demonstrate antimicrobial performance and clinical utility in wound care.
Formulation optimisation, material characterisation and laboratory-scale manufacturing for topical wound products and prototypes.
In vitro microbiology testing including assays for biofilm prevention and eradication and testing against priority and drug-resistant pathogens.
Quality management system oversight and regulatory compliance support for medical device development, including personnel eligible to act as a Qualified Person (QP).
Preparation and support for regulatory filings and interactions with regulators, drawing on experience with multiple FDA 510(k) submissions and device classification issues.
Design and conduct of preclinical in vitro studies, case studies and clinical evaluations to demonstrate antimicrobial performance and clinical utility in wound care.
Formulation optimisation, material characterisation and laboratory-scale manufacturing for topical wound products and prototypes.
In vitro microbiology testing including assays for biofilm prevention and eradication and testing against priority and drug-resistant pathogens.
Quality management system oversight and regulatory compliance support for medical device development, including personnel eligible to act as a Qualified Person (QP).
Expertise Areas
- Advanced wound care product development
- Antimicrobial technology development focused on reactive oxygen species
- Clinical evaluation and case-study generation for wound therapies
- Microbiology and biofilm testing
Key Technologies
- Reactive oxygen species generation (hydrogen peroxide) for antimicrobial use
- Topical gel formulations using bioengineered matrices
- Polymeric matrix delivery systems
- In vitro biofilm prevention and eradication assays
News & Updates
The FDA is proposing a new classification scheme for antimicrobial wound dressings based on antimicrobial resistance concern, which could impact the market and development of silver-based dressings.
The FDA is proposing a new classification scheme for antimicrobial wound dressings based on antimicrobial resistance concern, which could impact the market and development of silver-based dressings.